Abstract
The aim of the present study was to evaluate the clinical efficacy between manual buffy coat-derived platelet concentrates (PCs) and automated apheresis platelet concentrates (APCs) in terms of their therapeutic effects. The corrected count increment (CCI) was calculated according to detected differences in platelet concentration in patients who underwent transfusion of APCs (group I, 72 cases) or PCs derived from buffy coat (group II, 83 cases). The clinical efficacy was assessed in terms of the CCI and clinical symptoms. The mean 1 h CCI was 13.56±4.45 and 24 h CCI was 8.67±4.21 in group I, while the mean 1 h CCI was 15.83±4.65 and 24 h CCI was 9.57±3.36 in group II. The effective rates judged by CCI for groups I and II were 53 and 64%, respectively. In conclusion, the clinical effectiveness of manual PCs was similar to that for APCs; thus, it could be utilized for clinical use.
Introduction
Thrombocytopenia is a common and severe complication in cancer patients, often resulting from the malignancy itself or as a side effect of intensive chemotherapy and radiotherapy. Platelet transfusions are critical for preventing life-threatening hemorrhages. Currently, two main preparation methods exist: automated apheresis (APCs) and manual buffy coat-derived concentrates (PCs). While APCs are generally preferred for their high yield and lower immunogenicity, they are often expensive and subject to supply shortages. This study investigates whether manual PCs can serve as a clinically equivalent alternative to APCs in managing tumor-related thrombocytopenia.
Methods
A comparative study was conducted involving 155 tumor patients at the Affiliated Cancer Hospital of Zhengzhou University. Patients were divided into two groups:
- Group I (n=72): Received automated APCs.
- Group II (n=83): Received manual buffy coat-derived PCs.
The primary outcome measure was the Corrected Count Increment (CCI), calculated at 1 hour and 24 hours post-transfusion. Success was defined as a 1-hour CCI > 7.5 and a 24-hour CCI > 4.5. Additionally, clinical symptoms (reduction in bleeding) and adverse reactions were monitored. Before transfusion, the physical characteristics and platelet content of all products were analyzed.
Results
The analysis of platelet products revealed that approximately four units of manual PCs are required to match the platelet yield of a single apheresis bag (0.61 vs 2.34 x 10¹¹ platelets).
In terms of clinical efficacy, both groups showed comparable results. The manual PC group (Group II) demonstrated slightly higher mean CCI values at both 1 hour (15.83 ± 4.65) and 24 hours (9.57 ± 3.36) compared to the APC group (13.56 ± 4.45 and 8.67 ± 4.21, respectively). The effective rate based on CCI was 64% for manual PCs and 53% for APCs.
Statistical analysis (p > 0.05) confirmed that there were no significant differences in efficacy between the two methods. However, the manual PC group experienced a higher incidence of allergic reactions (8.43% vs. 4.17%), likely due to exposure to multiple donors.
Discussion
The findings suggest that manual buffy coat-derived platelets are functionally equivalent to apheresis-derived platelets. Despite the common clinical preference for APCs, manual PCs provide a reliable therapeutic effect for tumor patients. The slightly higher rate of allergic reactions in the manual group is a known trade-off of pooled products, which could potentially be mitigated through improved filtration or leukocyte depletion techniques.
Conclusion
Manual buffy coat-derived platelet concentrates are a viable and effective alternative to automated apheresis products. Their use can help optimize limited blood resources and ensure that cancer patients receive necessary transfusion support even when high-tech apheresis supplies are constrained.
Summary updated